Feed / CYTK

Cytokinetics, Incorporated

CYTK

Healthcare · 76.87 -0.4% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Cytokinetics, Incorporated's move is being confirmed by its market group.

CYTK accounts for 1.6% of the group's measured movement across 5.6 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 16%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveFlat / inactive path#9 of 12 by movement share
Group movement share1.6%Absolute path energy—not portfolio weight
Relative path-0.36%flat
Effective breadth5.6 / 12balanced
Relative alignment7/12upside path · 1 counter-moving
Capital-flow agreement16%not yet clean
SEQUENCE READ

No material onset for CYTK could be timestamped inside the aligned 5-minute window.

EVIDENCE COVERAGE

10 of 16 members in Clinical Biopharmaceuticals are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 11 of 16 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NBIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.

Watch this read

Who this business touches

The relationships behind CYTK

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

SNYSanofipartnerFeb 26, 2026

In December 2024, Corxel assigned its rights and obligations under our license and collaboration agreement to Genzyme Corporation, an affiliate of Sanofi.

AMGNAmgen Inc.investeeFeb 26, 2026

2017 RP Omecamtiv Mecarbil Royalty Purchase Agreement In February 2017, we entered into the RP OM RPA pursuant to which we sold a portion of our right to receive royalties from Amgen on future net sales of omecamtiv mecarbil to RPFT for a one-time payment of…

Depended on by

EWTXEdgewise Therapeutics, Inc.competitorMay 7, 2026

In the field of emerging treatments for HCM, competitors include Bristol-Myers Squibb (BMS), Cytokinetics, Imbria Pharmaceuticals, Lexicon Pharmaceuticals, and Celltrion, and Braveheart Bio.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 15 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

CYTK is currently a Participant in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.